DGAP-News: Vita 34 AG / Key word(s): Half Year Results/Half Year ReportVita 34 records moderate upward trend in the second quarter 30.08.2022 / 19:20 CET/CESTThe issuer is solely responsible for the content of this announcement.
Vita 34 records moderate upward trend in the second quarter
Leipzig, 30 August 2022 - Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), the leading cell bank in Europe and the third largest in the world, was able to benefit from a moderate upward trend in the further course of the first half of the year after an overall weaker start to the year. Although overall business development still falls short of potential, the company anticipates an improvement in the situation in the second half of the year.
As in the first quarter, revenues of EUR 32.1 million in the first six months were around three times as high as in the same period of the previous year (H1 2021: EUR 10.5 million) as a result of the merger with PBKM FamiCord. The reasons for the overall nevertheless restrained business development lie in a clearly perceptible decline in demand from new customers. At the beginning of the year, this was mainly related to the Omicron wave and was significantly exacerbated in the following months by the Ukraine conflict and the emerging energy price-driven crisis. Reluctance on the part of potential customers remained unchanged both in the Eastern and Southern European markets as well as in the DACH region. Since the middle of the second quarter, there has been a moderate upward trend in demand.
The intensified decline in demand from March onwards also had a correspondingly significant impact on the development of earnings. As the company deliberately refrained from implementing far-reaching cost-cutting measures in the personnel area and only implemented cost-cutting and cost-shifting measures to a certain extent and continued to invest in R&D and newly developing CDMO area, earnings before interest, taxes, depreciation and amortization (EBITDA) were negative at EUR -2.6 million (H1 2021: EUR 1.7 million). The negative trend was reinforced by a series of special effects amounting to around EUR 5 million, the extent of which was in line with forecast expectations. In addition to expenses for the business combination, restructuring and severance payments, this mainly includes the forecast special effect from the harmonization of accounting under IFRS 15 (revenue recognition) of around EUR 4 million in the first half of the year.
The key figures for business development are as follows:
The strong increase in inflation throughout Europe in recent months has also been reflected in a significant rise in prices for production-relevant raw materials and equipment, as well as in increased personnel costs. At the same time, however, the company managed to implement price increases in some markets to at least partially compensate for the increased cost base.
"We managed to increase the number of new contracts by an upper single-digit percentage compared to Q1 2022. We assess this trend as a good basis for the second half of the year. Provided that the general economic environment does not deteriorate significantly further," explains Jakub Baran, CEO of Vita 34 AG." In addition, we assumed in our annual forecast that we would be able to implement necessary measures in connection with IFRS-15 in the second half of the year and thus adequately counteract the special effect from the harmonization of accounting. We are pleased that we have now reached an agreement on this point. On the basis of an external opinion contractual adjustments while fully implemented will again enable us to account for our new customer contracts on the basis of economically realistic scenarios. Contrary to our original expectations, this will be reflected in our figures essentially from the fourth quarter onwards and only to a small extend in the third quarter. Nevertheless, this step will have a significant positive effect on our profitability from now on."
At the same time, the company continues to expect that the extensive investments made in the new expanding CDMO business area will result in the first sales from the fourth quarter of 2022 onwards.
Yesterday, the Company published a statement on the need to adjust its forecast. According to this, the contract changes introduced will essentially have a positive effect on consolidated sales and earnings from the fourth quarter onwards and only to a small extend in the third quarter. Accordingly, the third quarter is the last quarter in which this temporal shift has an impact on the revenue and EBITDA forecast in the form of a non-cash negative accounting effect of EUR about -2.5 million. In addition, contrary to the original planning, major location measures in individual markets will now already be completed in the second half of 2022. These underlying steps will add up to a one-off special effect of EUR -1.5 million in the course of the year. Against the backdrop of the aforementioned effects and the continuing difficult market environment, the forecast ranges for consolidated sales were adjusted to EUR 65 to 72 million (previously: EUR 68 to 75 million) and for EBITDA to EUR -6.0 to -3.0 million (previously: EUR -2 to +1 million) in the course of the publication of August 29, 2022.
Contact: Ingo MiddelmenneInvestor RelationsVita 34 AGPhone: +49 (0341) 48792 - 0Mobile: +49 (0174) 9091190E-Mail: ingo.middelmenne@vita34.de
Company profile
Vita 34 was founded in Leipzig in 1997 and is today by far the leading cell bank in Europe and the third largest worldwide. As the first private cord blood bank in Europe and a pioneer in cell banking, the company has since been offering collection logistics, processing and storage of stem cells from umbilical cord blood, umbilical cord tissue and other postnatal tissue as a full-service provider for cryopreservation. Customers from around 50 countries have already provided for the health of their family with more than 850,000 units of stored biological materials at Vita 34.
30.08.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at http://www.dgap.de
Visit link:
Vita 34 records moderate upward trend in the second quarter - PharmiWeb.com
- I Peace manufactures 100 lines of GMP iPS Cells cumulatively - PR Newswire - January 1st, 2025
- Cell banking: Definition, Process & Manufacturing - December 27th, 2024
- Stem cell banking: benefits and challenges - faCellitate - December 25th, 2024
- Stem Cell Banking Market to Surpass Value of USD 18.65 - GlobeNewswire - December 17th, 2024
- Stem Cell Banking Market Types and Applications, Drivers, - openPR - December 13th, 2024
- Human Pluripotent Stem Cell Banking - December 5th, 2024
- Cord Blood Banking 101: What Expectant Parents Need to Know - DNA India - December 5th, 2024
- Stem Cell Banking Market by Type, Service, Source, Application - Global ... - November 29th, 2024
- ViaCord Cord Blood Banking - November 25th, 2024
- What Is Stem Cell Banking? - Celltex Therapeutics Corporation - November 22nd, 2024
- Stem Cell/Cord Blood Banking Market Size, Trend Analysis, Share, Competitive Analysis, And Forecast To 2033 - openPR - November 20th, 2024
- Medeze Group Reaffirms Its International Standards Degree of Stem Cell Banking Services - KAOHOON INTERNATIONAL - November 8th, 2024
- Adult Stem Cells Storage & Banking | Preserve Stem Cells Forever Labs - October 27th, 2024
- International Stem Cell Banking Initiative - October 27th, 2024
- SBS University hosts National Workshop on Stem Cell Banking - Garhwal Post - October 20th, 2024
- Stem Cell Banking Market Advancements and Opportunities in Cell Preservation and Research - openPR - October 18th, 2024
- The global leader in personal stem cell banking - October 15th, 2024
- Stem Cell Banking Outsourcing Industry to Witness Massive Growth (2024-2034) |CCBC, CBR, ViaCord, Esperite, Vcanbio, Boy Talented India - Talented... - October 15th, 2024
- Medeze, a stem cell banking service provider, will start trading on the Stock Exchange of Thailand on October 15 - Thailand Business News - October 15th, 2024
- Stem Cell Banking: Current Trends, Benefits, Emerging Issues and ... - October 14th, 2024
- Fundamental Principles of Stem Cell Banking - PubMed - October 11th, 2024
- Cell Bank Production - ATCC - October 10th, 2024
- Stem Cell Banking Market Size Projected to Reach USD 16.55 Billion, Globally, by 2030 at 15.6% CAGR - EIN News - October 10th, 2024
- The Growing Importance of Stem Cell Banking in the UAE - October 4th, 2024
- American Cell Technology | Stem Cell Banking in the United States - September 30th, 2024
- Cell Banking - About Stem Cells - September 30th, 2024
- What to Know about Stem Cell Banking & Storage for Future Health - September 30th, 2024
- What is Stem Cell Banking? - azolifesciences.com - September 30th, 2024
- Stem Cell Banking Market Growth and Innovation 2024: Business - openPR - July 10th, 2024
- Stem Cell Banking Market Size To Surpass USD 19.29 Billion By 2030, Exhibiting A CAGR Of 13.69% As Revealed... - WhaTech - March 18th, 2024
- Stem Cell Banking Market Size, Share, Competitive Landscape and Trend Analysis and Industry Forecast, - EIN News - January 18th, 2024
- Stem Cell Banking Market Predicted to Witness Steady Growth ... - Digital Journal - September 8th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR 15.6% - EIN News - September 7th, 2023
- Stem Cell Banking Market Trends: Industry Analysis and Growth Projections Through 2030 - Benzinga - September 3rd, 2023
- Stem Cell Banking Market Report: Analysis of Effective Business ... - Digital Journal - August 30th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | CAGR of 15.6% - openPR - July 19th, 2023
- Stem Cell Banking Market expected to reach USD 16,474.30 million by 2029 - openPR - July 8th, 2023
- Global Stem Cell Banking Market is expected to reach a market size of ~US$ 15 billion by 2028: Ken Research - openPR - June 8th, 2023
- Stem Cell Banking Market: CAGR of 8.2% and Market Valuation ... - KaleidoScot - June 8th, 2023
- Cord Stem Cell Banking Market Size to Surpass USD 45.64 Billion with CAGR of 22% by 2030 - openPR - June 4th, 2023
- Forecasting the Future of the Stem Cell Banking Market : Trends and Insights | CCBC, Crioestaminal, Esperite, - openPR - April 29th, 2023
- Stem Cell Banking Market Expected To Reach $16.55 Billion by 2030 | Current Trends and Industry Analysis - EIN News - April 27th, 2023
- Stem Cell Banking Offers Health And Investment Opportunity - ValueWalk - April 21st, 2023
- Stem Cell Banking Offers Health and Investment Opportunity ... - SavingAdvice.com - April 19th, 2023
- Cord Stem Cell Banking Market to Influence the Value of USD 45.64 Billion by 2030 - openPR - April 12th, 2023
- Stem Cell Banking Market Size Expected to Reach USD 16,474.30 Million by 2029 with 16.1% CAGR - openPR - March 29th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- What is Stem Cell Banking? | Cells4Life - March 19th, 2023
- Stem Cell Banking Market Top-Players And Qualitative Future ... - Digital Journal - February 13th, 2023
- Global Stem Cell Banking Market Overview, Regional Analysis, Market Share and Competitive Analysis - openPR - February 4th, 2023
- What is Stem Cell Banking? | Stem Cell Preservation in India | Stem ... - January 7th, 2023
- Stem Cell & Cord Blood Banking Dubai, UAE - CellSave Arabia - January 5th, 2023
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - January 5th, 2023
- Private stem cell banking & genetic screening | Future Health Biobank - December 24th, 2022
- Stem Cell Banking Outsourcing Market is anticipated to expand at a ... - Digital Journal - December 20th, 2022
- Stem Cell Banking market size is estimated to be worth USD 1789 million in 2021 and is forecast to a readjuste - openPR - December 15th, 2022
- Stem Cell Banking Market To Reach USD 2927.2 Million By 2028 With A CAGR of 7.2% | Valuates Reports - Yahoo Finance - December 11th, 2022
- Stem Cell Banking Market registering a CAGR of 16.1% by forecast 2029 - openPR - December 1st, 2022
- Stem Cell Banking Industry 2022 - 2028 Market Analysis by Regions, Types and Application - openPR - November 6th, 2022
- Stem Cell Banking & Therapy In India | ReeLabs - October 25th, 2022
- Worldwide Stem Cell Banking Industry to 2027 - Rising Number of Fatal ... - October 25th, 2022
- Global Stem Cell Umbilical Cord Blood (UCB) Market Report 2022-2026: Increased Federal Investment in Stem Cell Therapy, and the Advent of Cord Blood... - October 25th, 2022
- Placental Stem Cell Therapy Market - Know the Latest Profit Sources of the Industry - openPR - October 18th, 2022
- Outlook on the Cord Blood Banking Services Global Market to 2027 - by Component, Storage Services, Application and Region - GlobeNewswire - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 12th, 2022
- News from the world of Education: October 12, 2022 - The Hindu - October 12th, 2022
- Stemcord | Home - October 9th, 2022
- Global Cord Blood Banking Market - Competition Forecast and Opportunities, 2027 - Yahoo Finance - October 9th, 2022
- Cell Banking Outsourcing Market Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2031 The Colby Echo News - The Colby Echo... - October 4th, 2022
- Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands - Business Wire - September 29th, 2022
- Biobanking Market Size to Surge at the CAGR of 5.9% from 2022-2031 - Digital Journal - September 19th, 2022
- Stem Cell Banking Solutions | Hope Biosciences - September 19th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - Benzinga - September 17th, 2022
- Stem Cell Banking Market to Witness Massive Growth by 2029 | CCBC, CBR - Fighting Hawks Magazine - Fighting Hawks Magazine - September 15th, 2022
- Stem Cell Banking Market Analysis, 2031: Advancements in the field of Regenerative Medicine - BioSpace - September 15th, 2022
- Stem Cell Therapy Market worth $558 million by 2027 Exclusive Report by MarketsandMarkets - GlobeNewswire - September 15th, 2022
- Cord Blood Banking Services Market Size Estimated to Reach $3.6 Billion By 2027 at a CAGR of 11.8% During Forecast Period 2022-2027. - Digital Journal - August 30th, 2022
- Applied StemCell expands manufacturing facility to support cell and gene therapies - BioPharma-Reporter.com - August 30th, 2022
- What is Cord Blood Banking? - Benzinga - August 30th, 2022
- dental stem cell banking - National Dental Pulp Laboratory - August 29th, 2022
Recent Comments